Article
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.
American journal of hematology - 1 Jan 2017
Patnaik Mrinal M, Barraco Daniela, Lasho Terra L, Finke Christy M, Hanson Curtis A, Ketterling Rhett P, Gangat Naseema, Tefferi Ayalew
Abstract excerpt
DNMT3A mutations are seen in ∼5% of patients with chronic myelomonocytic leukemia (CMML) and thus far, have had an indeterminate prognostic impact on survival. We carried out this study to assess the prognostic impact of DNMT3A mutations on a larger informative cohort of CMML patients (n = 261). DNMT3A mutations were seen in 6% (n = 16); 56% (n = 9) male, with a median age of 64 years. Eighty-one % of DNMT3A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.